vs
Side-by-side financial comparison of Lakeside Holding Ltd (LSH) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $7.0M, roughly 2.0× Lakeside Holding Ltd). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -22.6%, a 98.3% gap on every dollar of revenue.
Lakeside Press was a Chicago publishing imprint under which the RR Donnelley Company produced fine books as well as mail order catalogs, telephone directories, encyclopedias, and advertising. The Press was best known for its high quality editions for the Chicago Caxton Club as well as the Lakeside Classics, a series of fine reprints.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
LSH vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.0M | $13.7M |
| Net Profit | $-1.6M | $10.4M |
| Gross Margin | 27.2% | — |
| Operating Margin | -21.3% | -86.5% |
| Net Margin | -22.6% | 75.7% |
| Revenue YoY | 95.0% | — |
| Net Profit YoY | 18.7% | 179.1% |
| EPS (diluted) | $-0.08 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.0M | $13.7M | ||
| Q3 25 | $6.1M | $19.1M | ||
| Q2 25 | $6.3M | $8.1M | ||
| Q1 25 | $3.8M | $2.9M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.1M | — |
| Q4 25 | $-1.6M | $10.4M | ||
| Q3 25 | $-1.4M | $-16.3M | ||
| Q2 25 | $-893.1K | $-15.8M | ||
| Q1 25 | $-1.1M | $-13.3M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | $-1.3M | — |
| Q4 25 | 27.2% | — | ||
| Q3 25 | 18.2% | — | ||
| Q2 25 | 26.7% | — | ||
| Q1 25 | 18.8% | — | ||
| Q4 24 | -1.2% | — | ||
| Q3 24 | 12.8% | — |
| Q4 25 | -21.3% | -86.5% | ||
| Q3 25 | -20.8% | -10.1% | ||
| Q2 25 | -8.9% | -177.7% | ||
| Q1 25 | -28.2% | -472.7% | ||
| Q4 24 | -55.6% | — | ||
| Q3 24 | -32.5% | — |
| Q4 25 | -22.6% | 75.7% | ||
| Q3 25 | -22.2% | -85.4% | ||
| Q2 25 | -14.2% | -196.0% | ||
| Q1 25 | -28.2% | -452.7% | ||
| Q4 24 | -54.1% | — | ||
| Q3 24 | -32.7% | — |
| Q4 25 | $-0.08 | $-3.74 | ||
| Q3 25 | $-0.09 | $-0.11 | ||
| Q2 25 | $-0.11 | $-0.16 | ||
| Q1 25 | $-0.14 | $-0.18 | ||
| Q4 24 | $-0.26 | — | ||
| Q3 24 | $-0.18 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6M | $137.5M |
| Total DebtLower is stronger | $2.4M | — |
| Stockholders' EquityBook value | $12.2M | $35.3M |
| Total Assets | $24.3M | $154.7M |
| Debt / EquityLower = less leverage | 0.20× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6M | $137.5M | ||
| Q3 25 | $4.5M | $103.8M | ||
| Q2 25 | $5.0M | $121.6M | ||
| Q1 25 | $1.5M | $89.1M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $2.7M | — |
| Q4 25 | $2.4M | — | ||
| Q3 25 | $2.4M | — | ||
| Q2 25 | $1.4M | — | ||
| Q1 25 | $774.2K | — | ||
| Q4 24 | $784.8K | — | ||
| Q3 24 | $589.9K | — |
| Q4 25 | $12.2M | $35.3M | ||
| Q3 25 | $7.0M | $-8.1M | ||
| Q2 25 | $2.8M | $7.1M | ||
| Q1 25 | $749.8K | $10.7M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $3.6M | — |
| Q4 25 | $24.3M | $154.7M | ||
| Q3 25 | $18.6M | $133.7M | ||
| Q2 25 | $14.4M | $133.8M | ||
| Q1 25 | $9.9M | $103.7M | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $10.8M | — |
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 0.48× | — | ||
| Q3 24 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-453.5K | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-453.5K | $-2.0M | ||
| Q3 25 | $-4.0M | $-17.5M | ||
| Q2 25 | $-483.7K | $-14.5M | ||
| Q1 25 | $-238.3K | $29.0M | ||
| Q4 24 | $-530.2K | — | ||
| Q3 24 | $-1.4M | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-497.4K | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | $-560.5K | — | ||
| Q3 24 | $-1.4M | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | -7.9% | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | -15.6% | — | ||
| Q3 24 | -34.5% | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.2% | 5.0% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.1% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
XLO
Segment breakdown not available.
